Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.39B 3.19B 2.92B 5.45B 370B 5.5B 38.26B 14.83B 189B 14.47B 14.16B 612B P/E 2024
15.9x
P/E 2025 13.9x
Enterprise Value 3.15B 2.77B 2.61B 2.38B 4.45B 302B 4.49B 31.25B 12.12B 154B 11.82B 11.56B 500B EV / Sales 2024
4.02x
EV / Sales 2025 3.67x
Free-Float
99.94%
Yield 2024 *
-
Yield 2025 -
1 day+0.03%
3 months+0.29%
6 months+35.03%
Current year+34.92%
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 5
Extreme 5
32.56
10 years 0.94
Extreme 0.9414
32.56
Manager TitleAgeSince
Chief Executive Officer 65 2023-12-31
Director of Finance/CFO 55 2023-12-31
Chief Tech/Sci/R&D Officer 62 2025-05-31
Director TitleAgeSince
Director/Board Member 48 2026-07-14
Director/Board Member - 2026-07-14
Director/Board Member - 2026-07-14
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Issuer sale

Director

-63,583 0.0519%
7/15/26 Issuer sale

Director

-130,857 0.1069%
7/15/26 Issuer sale

Executive/Senior Manager

-1,051,183 0.8587%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--% - - 3.85B
Average +0.03%
Weighted average by Cap. +0.03%

Financials

2024 2025
Net sales 492M 432M 407M 372M 696M 47.18B 702M 4.88B 1.89B 24.05B 1.85B 1.81B 78.09B 589M 518M 488M 446M 833M 56.51B 840M 5.85B 2.27B 28.81B 2.21B 2.16B 93.54B
Net income 164M 144M 136M 124M 232M 15.72B 234M 1.63B 631M 8.02B 615M 602M 26.03B 214M 188M 177M 162M 303M 20.56B 306M 2.13B 825M 10.48B 805M 787M 34.04B
Net Debt -514M -452M -426M -389M -728M -49.35B -734M -5.1B -1.98B -25.16B -1.93B -1.89B -81.69B -706M -621M -585M -535M -999M -67.77B -1.01B -7.01B -2.72B -34.55B -2.65B -2.59B -112B
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. CPRX Stock